Teva Q3 revenues $3.9B (-2% YoY), non-GAAP EPS $0.59 vs $0.58; reaffirms FY guidance

TEVA PHARMACEUTICAL INDUSTRIES LTD

2021-Q3 EPS reported $0.52 revenue$11,778,000,000

GAAP diluted EPS $0.26 on net income $292M (vs loss $4.349B in Q3 2020).
Non-GAAP diluted EPS $0.59 on net income $651M (up from $0.58).
Free cash flow $795M; operating cash flow $529M.
FY 2021 outlook: revenue $16.0-16.4B, adj. EBITDA $4.8-5.1B, EPS $2.50-2.70, FCF $2.0-2.3B.
Announced collaboration with MODAG GmbH for movement disorder products; issued Sustainability-Linked Bond.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.